Nuria Ribelles
Nuria Ribelles, MD, PhD is an expert in Oncology at Hospital Clínico Universitario Virgen de la Victoria (Spain). As of November 2026, ScienceLeadR ranks Nuria Ribelles in the top 1% of experts worldwide for Breast Diseases. Nuria Ribelles has authored 138 publications, the most recent in 2026, and is an investigator in 11 clinical trials. SLR score: 468 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Hepatology - Biochemistry - Informatics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 138
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial. PMID 42957778 — circulating tumor dna, breast neoplasms, molecular biology, neoplasms, drug therapy, fluorodeoxyglucose f18, breast, therapeutics, chemotherapy | Nat Med Top journal | 2026 | 0 |
| Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study. PMID 42288057 — breast neoplasms, neoplasms, cohort studies, drug therapy, breast, therapeutics, chemotherapy | Breast | 2026 | 0 |
| Clinical features and management for CDK4/6 inhibitor-DILI. PMID 42067190 — absenteeism, breast neoplasms, pharmaceutical preparations, adrenal cortex hormones, neoplasms, liver, drug-related side effects and adverse reactions, breast, therapeutics, bilirubin | JHEP Rep | 2026 | 0 |
| Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy. PMID 41333222 — triple negative breast neoplasms, breast neoplasms, neoplasms, drug therapy, chemotherapy, adjuvant, breast, therapeutics, capecitabine, data analysis, chemotherapy | Front Oncol | 2025 | 0 |
| SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025). PMID 41182651 — breast neoplasms, neoplasms, breast, therapeutics | Clin Transl Oncol | 2025 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map